Adelaide Medical School
Faculty of Health and Medical Sciences
Type 2 diabetes is a disease of abnormal systemic metabolism, and yet the most common cause of death is cardiovascular disease. Cher-Rin's current research aims to decipher the molecular mechanism of metabolic and cardiovascular dysfunction, with the ultimate aim of using this information to develop targeted therapeutics.
She has 2 key research questions (and projects):
1. To investigate the impact of altered substrate/fuel selection to the diabetic heart, with particular focus on the ketone bodies
2. To investigate the interactions between DNA damage and diabetic heart
Currently, she and her colleagues are looking for enthusiastic, curious and motivated students to join the lab. For further information about the research and potential project, please send her an email at firstname.lastname@example.org
- Cardiac metabolism, pharmacology & physiology
- Diabetes and diabetic heart
- Takotsubo (stress) syndrome
- Evidence-based medicine, systematic review and meta-analysis
Cher-Rin has >10 years experience as clinical pharmacist, having worked at both tertiary hospital as well as community pharmacy in Australia. As an academic pharmacist, her broad areas of research interests encompass pharmacology, molecular cardiology and metabolism. She undertook her Ph.D. training at University of Adelaide, with support from the Australian Government National Health & Medical Research Council (NHMRC). Her doctoral thesis focuses on the pharmacological manipulation of cardiac metabolism (using perhexiline, its enantiomers and antiarrhythmics include amiodarone and dronedarone), and the effects on patients with Type 2 diabetes. During which time, she also performed investigations into the pathophysiology of Takotsubo (stress) syndrome and evaluated the interactions between insulin and nitric oxide signaling.
In 2016, Cher-Rin was awarded the Nuffield Medical Fellowship which allowed her to join the Department of Physiology, Anatomy & Genetics at University of Oxford (UK). Here, she was trained under the supervision of Professors Kieran Clarke and Rhys Evans. She worked on a number of projects, with particular focus on the investigations of the impact of ketone bodies on diabetes and the diabetic heart.
In 2019, with support from NHMRC and National Heart Foundation of Australia, Cher-Rin returns to Adelaide to continue her research.
Date Position Institution name 2019 Postdoctoral Fellow University of Adelaide 2016 - 2019 Oxford Nuffield Medical Fellow University of Oxford 2008 - 2016 Rotating pharmacist, Pharmacist registrar, Senior pharmacist The Queen Elizabeth Hospital, SA Department of Health
Language Competency Chinese (Cantonese) Can read, write, speak and peer review Chinese (Mandarin) Can read, write, speak and peer review English Can read, write, speak and peer review Malay Can read, write and speak
Date Institution name Country Title 2017 University of Adelaide Australia Ph.D. 2006 University of South Australia Australia Bachelor of Pharmacy
Year Citation 2020 Horowitz, J. D., & Chong, C. -R. (2020). Matrix metalloproteinase-2 activation: critical to myocardial contractile dysfunction following ischaemia-reperfusion.. Cardiovascular research, 116(5), 876-878.
2019 Roberts, G., Chong, C., Quinn, S., Cameron-Collins, S., Forbes, H., Johnson, J., . . . Wisdom, A. (2019). Evaluation of the effect of direct oral anticoagulant availability on hospital presentations for bleeding related to oral anticoagulation in South Australia. Journal of Pharmacy Practice and Research, 49(6), 517-524.
2019 Drury, N. E., Yim, I., Patel, A. J., Oswald, N. K., Chong, C. -R., Stickley, J., & Jones, T. J. (2019). Cardioplegia in paediatric cardiac surgery: a systematic review of randomized controlled trials. Interactive CardioVascular and Thoracic Surgery, 28(1), 144-150.
DOI Scopus1 WoS1 Europe PMC1
2019 Imam, H., Nguyen, T., De Caterina, R., Nooney, V., Chong, C., Horowitz, J., & Chirkov, Y. (2019). Impaired adenylate cyclase signaling in acute myocardial ischemia: Impact on effectiveness of P2Y<inf>12</inf> receptor antagonists. Thrombosis Research, 181, 92-98.
DOI Scopus1 WoS1
2018 Timm, K., Apps, A., Miller, J., Ball, V., Chong, C., Dodd, M., & Tyler, D. (2018). Assessing the optimal preparation strategy to minimize the variability of cardiac pyruvate dehydrogenase flux measurements with hyperpolarized MRS. NMR in Biomedicine, 31(9), e3992.
2018 Drury, N. E., Patel, A. J., Oswald, N. K., Chong, C. -R., Stickley, J., Barron, D. J., & Jones, T. J. (2018). Randomized controlled trials in children’s heart surgery in the 21st century: a systematic review. European Journal of Cardio-Thoracic Surgery, 53(4), 724-731.
DOI Scopus1 WoS1
2018 Ajaero, C., Chong, C. -R., Procter, N., Liu, S., Chirkov, Y., Heresztyn, T., . . . Horowitz, J. (2018). Does cardiac resynchronization therapy restore peripheral circulatory homeostasis?. ESC heart failure, 5(1), 129-138.
2017 Chong, C. -R., Clarke, K., & Levelt, E. (2017). Metabolic remodelling in diabetic cardiomyopathy. Cardiovascular Research, 113(4), 422-430.
DOI Scopus38 WoS33 Europe PMC16
2016 Phuong, H., Choi, B., Chong, C., Raman, B., & Horowitz, J. (2016). Can perhexiline be utilized without long-term toxicity? A clinical practice audit. Therapeutic Drug Monitoring, 38(1), 73-78.
DOI Scopus6 WoS5 Europe PMC2
2016 Chong, C., Sallustio, B., & Horowitz, J. (2016). Drugs that Affect Cardiac Metabolism: focus on Perhexiline. Cardiovascular Drugs and Therapy, 30(4), 399-405.
DOI Scopus9 WoS9 Europe PMC5
2016 Chong, C., Ong, G., & Horowitz, J. (2016). Emerging drugs for the treatment of angina pectoris. Expert Opinion on Emerging Drugs, 21(4), 365-376.
DOI Scopus4 WoS4 Europe PMC4
2015 Singh, K., Chong, C., Nguyen, T., Stansborough, J., & Horowitz, J. (2015). Reply: Takotsubo syndrome is a systemic, rather than merely a cardiac, disease: Possible effects on the systemic and pulmonary vasculature. Heart Lung and Circulation, 24(4), 417-418.
2015 Liu, S., Ngo, D., Chong, C., Amarasekera, A., Procter, N., Licari, G., . . . Horowitz, J. (2015). Suppression of neutrophil superoxide generation by BNP is attenuated in acute heart failure: a case for 'BNP resistance'. European Journal of Heart Failure, 17(5), 475-483.
DOI Scopus5 WoS5 Europe PMC3
2015 Chong, C., Liu, S., Licari, G., Heresztyn, T., Chirkov, Y., Ngo, D., & Horowitz, J. (2015). Reversal of hyperglycemia: effects on nitric oxide signaling. American Journal of Medicine, 128(4), 427-430.
DOI Scopus3 WoS3 Europe PMC2
2015 Angus, D., Barnato, A., Bell, D., Bellomo, R., Chong, C., Coats, T., . . . Young, J. (2015). A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe Investigators. Intensive Care Medicine, 41(9), 1549-1560.
DOI Scopus203 WoS185 Europe PMC137
2015 Chong, C., Drury, N., Licari, G., Frenneaux, M., Horowitz, J., Pagano, D., & Sallustio, B. (2015). Stereoselective handling of perhexiline: implications regarding accumulation within the human myocardium. European Journal of Clinical Pharmacology, 71(12), 1485-1491.
DOI Scopus6 WoS5 Europe PMC3
2015 Procter, N. E., Ball, J., Heresztyn, T., Nooney, V. B., Liu, S., Chong, C. -R., . . . Horowitz, J. D. (2015). Subtle renal dysfunction and bleeding risk in atrial fibrillation: symmetric dimethylarginine predicts HAS-BLED score.. American journal of cardiovascular disease, 5(2), 101-109. 2015 Horowitz, J., Chong, C., Ngo, D., & Sverdlov, A. (2015). Effects of acute hyperglycaemia on cardiovascular homeostasis: Does a spoonful of sugar make the flow-mediated dilatation go down?. Journal of Thoracic Disease, 7(12), 607-611.
DOI Scopus3 WoS3 Europe PMC2
2014 Procter, N., Chong, C., Sverdlov, A., Chan, W., Chirkov, Y., & Horowitz, J. (2014). Aging of platelet nitric oxide signaling: pathogenesis, clinical implications, and therapeutics. Seminars in Thrombosis and Hemostasis, 40(6), 660-668.
DOI Scopus7 WoS6 Europe PMC3
2014 Drury, N., Licari, G., Chong, C., Howell, N., Frenneaux, M., Horowitz, J., . . . Sallustio, B. (2014). Relationship between plasma, atrial and ventricular perhexiline concentrations in humans: insights into factors affecting myocardial uptake. British Journal of Clinical Pharmacology, 77(5), 789-795.
DOI Scopus7 WoS7 Europe PMC5
2014 Singh, K., Neil, C., Nguyen, T., Stansborough, J., Chong, C., Dawson, D., . . . Horowitz, J. (2014). Dissociation of early shock in Takotsubo cardiomyopathy from either right or left ventricular systolic dysfunction. Heart, Lung and Circulation, 23(12), 1141-1148.
DOI Scopus14 WoS16 Europe PMC9
2014 Chong, C., Chan, W., Nguyen, T., Liu, S., Procter, N., Ngo, D., . . . Horowitz, J. (2014). Thioredoxin-interacting protein: pathophysiology and emerging pharmacotherapeutics in cardiovascular disease and diabetes. Cardiovascular Drugs and Therapy, 28(4), 347-360.
DOI Scopus45 WoS44 Europe PMC31
2013 Chong, C., Neil, C., Nguyen, T., Stansborough, J., Law, G., Singh, K., & Horowitz, J. (2013). Dissociation between severity of takotsubo cardiomyopathy and presentation with shock or hypotension. Clinical Cardiology, 36(7), 401-406.
DOI Scopus33 WoS31 Europe PMC24
2013 Chong, C., Neil, C., Nguyen, T., Singh, K., & Horowitz, J. (2013). Reply. Clinical Cardiology, 36(10), E33.
2013 Chong, C., & Horowitz, J. (2013). Letters to the editor. Clinical Cardiology, 36(8), 492-493.
2012 Neil, C., Chong, C., Nguyen, T., & Horowitz, J. (2012). Occurrence of Tako-Tsubo cardiomyopathy in association with ingestion of serotonin/noradrenaline reuptake inhibitors. Heart, Lung & Circulation (Print Edition), 21(4), 203-205.
DOI Scopus26 WoS23 Europe PMC16
2012 Neil, C., Nguyen, T., Sverdlov, A., Chirkov, Y., Chong, C., Stansborough, J., . . . Horowitz, J. (2012). Can we make sense of takotsubo cardiomyopathy? An update on pathogenesis, diagnosis and natural history. Expert Review of Cardiovascular Therapy, 10(2), 215-221.
DOI Scopus18 Europe PMC11
Year Citation 2015 Chong, C. -R., Stansbourough, J., Raman, B., Nguyen, T., Neil, C., & Horowitz, J. (2015). Determinants of shock and mortality in Takotsubo cardiomyopathy: a cohort study. In EUROPEAN HEART JOURNAL Vol. 36 (pp. 1177-1178). London, ENGLAND: OXFORD UNIV PRESS.
2020 - 2022 C-R Chong, JD Horowitz, YY Chirkov. Project grant, Diabetes SA.
2019 - 2022 C-R Chong. Postdoctoral Fellowship, National Heart Foundation of Australia (co-funded with NHMRC) (ID: 102126)
2019 - 2022 C-R Chong. Peter Doherty Fellowship, National Health and Medical Research Council of Australia (NHMRC) (APP1162356).
2019 - 2020 C-R Chong. Early Career Fellowship, The Hospital Research Foundation (Awarded but did not accept due to acceptance of other fellowships)
2018 - 2019 C-R Chong, KN Timm. Pump priming grant, Oxford British Heart Foundation Centre of Research Excellence (RE/13/1/30181).
2016 - 2019 C-R Chong. Nuffield Medical Fellowship, Nuffield Dominions Trust Fund, University of Oxford.
2014 - 2016 C-R Chong. Dora Lush Biomedical Research Postgraduate Scholarship, NHMRC (APP1075767).
2014 C-R Chong. Affiliate Clinical Development Award, Cardiac Society of Australia and New Zealand (CSANZ)
2013, 2014 C-R Chong. Travelling fellowship, CSANZ.
2013 C-R Chong. Professional development grant, Young Professional Group, SA Department of Health
2011 - 13 C-R Chong. Student travel grant. Australasian Society of Clinical & Experimental Pharmacologists & Toxicologists
2005 C-R Chong Student Vacation Scholarship, The Cancer Council Australia
2005 C-R Chong Student Vacation Scholarship, Royal Adelaide Hospital Research Foundation (awarded but did not accept)
Connect With Me